🌟 ANKASCIN 568-R Earns NFSA Certification in Egypt, Paving the Way for International Expansion! 🌍 SunWay is thrilled to announce a major achievement in its overseas market strategy. #ANKASCIN568R Red Yeast Rice has received certification from the National Food Safety Authority (NFSA) of Egypt. This marks a historic milestone as the first Taiwanese Red Yeast Rice ingredient to obtain NFSA certification, solidifying SunWay’s presence and commitment to expanding into the African market. This significant milestone showcases SunWay Biotech International’s commitment to quality and safety and opens new doors to the African market. We are excited to continue our journey of global expansion, providing exceptional products to consumers worldwide!🚀 #SunWay #NFSA #Certification #GlobalExpansion #ANKASCIN568R #redyeastrice #Egypt #Africa
Exciting News! NIANGJIA Monascus Capsule is the first product of Taiwan recognized as a finalist for the Nutraingredient Asia Awards 2023: Botanical Product of the Year!
🌟 Exciting News! NIANGJIA Monascus Capsule is the first product of Taiwan recognized as a finalist for the Nutraingredient Asia Awards 2023: Botanical Product of the Year! 🌟 The specialty of #ANKASCIN568R is that it contains high levels of Monascin and Ankaflavin, showing anti-glycation, anti-inflammatory, and antioxidant abilities via #PPAR and #Nrf2 pathways to improve hyperglycemia, preventing fatty plaque accumulation for cardiovascular health, and ameliorating pathogenesis of Alzheimer’s decline to enhance cognitive function, having beneficial effects for healthy aging benefits. We are grateful to our dedicated R&D teams and the unwavering support from our valued customers. Let’s root for NIANGJIA Monascus Capsule to win the championship together! 💪 #NutraingredientAsia #Finalist #antiaging #CardiovascularHealth #BloodSugarManagement #NIUawards23 #RedYeastRice
🌟 Exciting News! Our US product, Red Yeast Rice, is a finalist for the Nutraingredient USA Awards 2023! 🌟 Did you know that 80% of Americans have low or moderate cardiovascular health, often requiring multiple medications and devices to manage their cholesterol and blood sugar levels? The vicious cycle of cardiovascular health and diabetes is well-known, but dyslipidemia and AGE accumulation accelerate organ inflammation and lead to such deterioration. Moreover, the Western diet, which is full of AGEs, and COVID-19 have aggravated this already grim scenario. At SunWay, we’re both grateful and thrilled that the judges for the NutraIngredients USA Awards have selected our US ANKASCIN 568-R product as a Finalist in the 2023 Botanical category. Let’s root for Red Yeast Rice to win the championship together! Learn more about how #ANKASCIN568 can manage cardiovascular health and blood sugar: https://sunway.cc/tw/ankascin-568-r-when-science-meets-market-trend-meets-government-policy/ #NutraingredientUSA #Finalist #RedYeastRice #CardiovascularHealth #BloodSugarManagement #Innovation Disclaimer: This communication is only intended for business-to-business. Nothing on this page is meant to be perceived as an approved claim by regulatory authorities.
“The superior effects of MS and AK in ANKASCIN® 568-R show significant results, from managing glycation and inflammation to improving hyperglycemia, hyperlipidemia, hypertension, and cognitive health. This novel ingredient is clinically proven, safe, has multiple applications in dietary supplements and functional food, is compliant with EU and US regulations, and provides excellent support for healthy aging.” According to the WHO, around one in ten people in Europe or US has diabetes, which means that if you go out with your relatives, there’s a good chance that the person you’re arm-in-arm with is someone who has diabetes. Chronic diabetic complications, including hyperlipidemia, hypertension, or Alzheimer’s disease, have been related to advanced glycation end product (AGE) accumulation. Glycation and AGEs lead to accelerated organ aging, thus causing the vicious cycle of tissue glycation and aging. However, the Western diet, which is full of AGEs, and COVID-19 have aggravated this already grim scenario. Reports show that patients with hyperglycemia and COVID-19 have a 2-to-4-fold risk of severe COVID-19 or death than those without diabetes. ANKASCIN® 568-R is a state-of-the-art ingredient containing high MS and AK levels. It addresses the root cause, mainly via PPARγ/Nrf2 pathways, to manage anti-glycation, antioxidant, and anti-inflammation and acts synergistically in improving the impairment of pancreatic β-cell function (blood glucose regulation), resolving lipid plaque accumulation in the blood […]
ANKASCIN 568-R has been recognized as a finalist for the Healthy Aging Ingredient of the Year at the Nutraingredients Awards 2023.
🎉We are thrilled to announce that ANKASCIN 568-R has been recognized as a finalist for the Healthy Aging Ingredient of the Year at the Nutraingredients Awards 2023. It is a cutting-edge ingredient that has been clinically proven to support blood glucose management, cardiovascular health, memory, cognitive health, and healthy aging. The uniqueness of ANKASCIN 568-R is that it contains high levels of Monascin and Ankaflavin, two active compounds that address the root cause of aging-related factors like advanced glycation end products, inflammatory cytokines, and reactive oxygen species via PPARγ/Nrf2 pathways. We are honored to be recognized for our commitment to innovation and excellence in the field of health and wellness. With growing public interest in anti-aging nutritional solutions, ANKASCIN 568-R fills a gap in the healthy aging supplement market.💪 Congratulations to all the finalists, and we look forward to continuing to drive innovation in the industry! Want to know more about ANKASCIN 568-R? contact us: email@example.com or call us at +886-2-2792-9568. #NutraingredientsAwards #HealthyAging #Innovation #ANKASCIN568R #Monascin #Ankaflavin #HealthAndWellness Disclaimer: This communication is only intended for business-to-business. Nothing on this page is meant to be perceived as an approved claim by regulatory authorities.
According to WHO, currently, more than 55 million people live with dementia worldwide, and there are nearly 10 million new cases every year. The most common type (60-70%) of dementia is Alzheimer’s disease (AD), a progressive disease characterized by memory loss, language breakdown, and eventually, death. The main pathological factor for AD is thought to be the progressive accumulation of amyloid beta (Aβ) peptides in the brain, generated by the cleavage of the amyloid precursor protein (APP) by a combination of β-secretases and γ-secretases. Hyperphosphorylation of tau, a microtubule-associated protein which aggregates to form tangles, also damages the brains of patients with AD. This year, we’re excited to announce that ANKASCIN® 568 product has successfully received a health certificate for “Anti-aging” Support. SunWay research demonstrates the protective effect of ANKASCIN® 568 in 4 aging models: Amyloid β-Infused Rats In this study, the effects of dietary administration of ANKASCIN® 568 on memory and learning abilities are confirmed in an animal model of AD rats infused with Aβ40 into the cerebral ventricle. During continuous Aβ40 infusion for 28 days, ANKASCIN® 568 administration potently reverses the memory deficit in the memory task. Aβ40 infusion increases acetylcholinesterase activity, reactive oxygen species, and lipid peroxidation and decreases total antioxidant status and superoxide dismutase activity in brain, but these damages were potently reversed by ANKASCIN® 568 administration. The protection provided […]
President Tsai Ing-wen met the 2022 Outstanding Biotechnology Industry Award winners on 23rd February. She emphasized that the government will continue to invest resources and adjust and amend relevant laws and regulations to improve the competitiveness of the biotechnology and medical industry continuously. Thus, technology and medical enterprises will develop more vigorously and create more welfare for the public. SunWay Biotech is committed to applying diverse and effective microorganisms and developing efficient and unique fermentation processes to provide high-quality products that ensure carefree health across the globe. In addition to winning the Taiwan BIO Award-Advanced National Innovation Award” for two consecutive years in 2020 and 2021, SunWay was honored to be awarded the Gold Award of 2022 Taiwan BIO Award! SunWay was invited to meet with President Tsai and discuss with the President and other participants how to continuously improve the competitiveness of the biotechnology and medical industry and become Taiwan’s next trillion-dollar industry! President John Pan of SunWay Biotech also expressed his gratitude to every colleague, customer, shareholder, and the most important technological inventor, Professor Tzu-Ming Pan, for allowing SunWay to create another sacred mountain for Taiwan! Source: Office of the President
Professor Tzu-Ming Pan and SunWay Biotech were triple awarded National Innovation Award Excelsior Award!
With the continuous innovation and advancements in R&D, the project “Study on Application of Red Mold Rice- Improvement of Memory and Learning Abilities of Alzheimer’s Patient and Metabolic Symptom”, researched by Professor Tzu-Ming Pan and SunWay Biotech research team, was triple awarded National Innovation Award Excelsior Award on 23 Dec 2022! For more information: https://reurl.cc/ROAejr
The first clinical study, which has been published in Heliyon, documents that Vigiis® 101-LAB significantly increases the bacterial counts of Bifidobacterium spp. and Lactobacillus spp. in feces in just one week, and maintains those elevated counts for four weeks. Thirty-six healthy subjects completed a randomized, double-blind, placebo-controlled 4-week study. The administration group took 50 mg Vigiis® 101-LAB /one capsule/day (= 5 billion NTU 101 CFU/day) for four weeks. After just one week of administration, the bacterial counts of Bifidobacterium spp. and Lactobacillus spp. in the feces of the treatment group were significantly higher than the placebo group. After four weeks, the treatment group’s bacterial counts of Bifidobacterium spp. and Lactobacillus spp. were 4.01-fold and 4.25-fold higher than the placebo group. These results indicate that supplementation of Vigiis® 101-LAB significantly increases good bacteria in the gut in just one week and maintains those elevated counts for four weeks. People can benefit from compelling effects of Vigiis® 101-LAB, efficacious and science-supported probiotic. John Pan, President of SunWay Biotech, commented that “It is important to maintain a healthy microbial balance in the gut microbiome with quality and clinically proven ingredients.” For more information, please get in touch with us: firstname.lastname@example.org Reference: Effects of Vigiis 101-LAB on a healthy population’s gut microflora, peristalsis, immunity, and anti-oxidative capacity: A randomized, double-blind, placebo-controlled clinical study. (link) […]
SunWay and MISA members provide grants to the “Cochlear Implant Specialty Program” for a better future.
SunWay Biotech has a longstanding commitment to Corporate Social Responsibility (CSR). Last week, SunWay and four other MISA members provided grants to the “Cochlear Implant Specialty Program” of Tri-Service General Hospital this November for patients with severe hearing loss to receive subsidies for cochlear implant surgery. According to statistics from the Ministry of Health and Welfare, until October 2022, there are still more than 20,000 people with severe or extremely severe hearing loss, including young children. They all look forward to hearing more sounds from this world. However, the hardware expenses required for cochlear implant surgery are costly. For many people with hearing loss and their families, it is not only a new hope but also a considerable medical burden. Through our CSR program, SunWay and four other MISA members provide grants to the “Cochlear Implant Specialty Account” of the Tri-Service General Hospital. We truly believe that it can bring those people a better future.